Drug Discovery World
FEBRUARY 20, 2024
The contract was awarded by the Defense Threat Reduction Agency’s (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program, through the Medical Chemical, Biological, Radiological, and Nuclear (CBRN) Defense Consortium (MCDC) requirement 22-05, ‘Adjuvant Activity to Vaccines Prototype’.
XTalks
APRIL 7, 2021
The test is intended for the detection of COVID-19 infection, either a recent or previous infection, as detected through an adaptive antibody immune response to SARS-CoV-2. The test involves self-collection of a fingerstick dried blood sample.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 23, 2020
All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. It will be funded by the U.S.
The Pharma Data
MARCH 29, 2022
W911QY-21-9-0001. AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
The Pharma Data
MARCH 25, 2022
The half-life extension more than triples the durability of its action compared to conventional antibodies;(11-13) data from the PROVENT Phase III trial show protection lasting at least six months.(14) W911QY-21-9-0001.
The Pharma Data
MAY 16, 2021
Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For media and investors only. Issued: London UK. About the Phase 2 study.
Bioengineer
JULY 15, 2021
But some patients develop resistance to current immunotherapies and others have cancers characterized by immunologically “cold” tumors, which evade or suppress the patient’s immune response against his or her cancer. This agent was developed by one of the co-authors, Jamey Weichert, Ph.D.,
Expert insights. Personalized for you.
52 
Let's personalize your content